Appendix C
Workshop Agenda and Participant List

November 1-2, 2005

Keck Center of the National Academies

500 Fifth Street, N.W. • Washington, D.C.

AGENDA

Tuesday, November 1, 2005

8:00 a.m.

Continental Breakfast

8:30 a.m.

Committee orientation (closed session)

9:00 a.m.

Workshop convocation and introductions −

Samuel Katz, chairman

9:30 a.m.

Polio eradication plan update

Looking ahead to the end-game: Bruce Aylward

Strategies for the OPV cessation era: Roland Sutter

Potential roles for an antiviral: Mark Pallansch

10:15 a.m.

Overview of poliovirus biology and pathogenesis

Eckard Wimmer



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement



Below are the first 10 and last 10 pages of uncorrected machine-read text (when available) of this chapter, followed by the top 30 algorithmically extracted key phrases from the chapter as a whole.
Intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text on the opening pages of each chapter. Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.

Do not use for reproduction, copying, pasting, or reading; exclusively for search engines.

OCR for page 69
Exploring the Role of Antiviral Drugs in the Eradication of Polio: Workshop Report Appendix C Workshop Agenda and Participant List November 1-2, 2005 Keck Center of the National Academies 500 Fifth Street, N.W. • Washington, D.C. AGENDA Tuesday, November 1, 2005 8:00 a.m. Continental Breakfast 8:30 a.m. Committee orientation (closed session) 9:00 a.m. Workshop convocation and introductions − Samuel Katz, chairman 9:30 a.m. Polio eradication plan update Looking ahead to the end-game: Bruce Aylward Strategies for the OPV cessation era: Roland Sutter Potential roles for an antiviral: Mark Pallansch 10:15 a.m. Overview of poliovirus biology and pathogenesis Eckard Wimmer

OCR for page 69
Exploring the Role of Antiviral Drugs in the Eradication of Polio: Workshop Report 10:45 a.m. Coffee Break 11:00 a.m. Introduction to potential targets Mutagenesis and RNAi: Raul Andino Capsid-binding compounds: Marc Collett Exploiting dominant inhibition: Karla Kirkegaard Protease inhibitors: Amy Patick 12:00 p.m. Organization of afternoon breakout sessions 12:30 p.m. Buffet Lunch 1:30 p.m. Breakout sessions 3:30 p.m. Coffee Break 3:45 p.m. Reports on breakout sessions and discussion 5:30 p.m. Adjourn Wednesday, November 2, 2005 8:00 a.m. Continental Breakfast 8:30 a.m. Organization of day 2 breakout groups 9:00 a.m. Working breakout group discussions 1. Public Health group: How would the drug be used in eradication? Who would patients be, how would they be identified and reached? What would be the advantages and disadvantages of the potential compounds identified in day 1 for different aspects of eradication? 2. Biology group: Evaluate each of the potential antivirals: how difficult would each be to develop, how likely to elicit resistance, how long would it take to develop, what would be its possible safety issues? 3. Development group: How much would each type of antiviral cost to develop? How hard might it be to move them

OCR for page 69
Exploring the Role of Antiviral Drugs in the Eradication of Polio: Workshop Report   through the approval process? Who might develop them? What are the likely timelines involved for each? What are possible sources of funding? 10:30 a.m. Coffee Break 10:45 a.m. Report from breakout group 1 and discussion 11:30 p.m. Report from breakout group 2 and discussion 12:15 p.m. Lunch 1:15 p.m. Report from breakout group 3 and discussion 2:00 p.m. Wrap-up: Designing and filling in a decision matrix for each compound 4:00 p.m. Adjourn PARTICIPANT LIST Jim Alexander, CDC Bruce Aylward, WHO Debra Birnkrant, Center for Drug Evaluation and Research, FDA Craig Cameron, Pennsylvania State University Marc Collett, ViroDefense, Inc. Walter Dowdle, The Task Force for Child Survival and Development Ellie Ehrenfeld, NIAID, NIH Diane Griffin, Johns Hopkins Bloomberg School of Public Health Matthias Gromeier, Duke University Medical Center Neal Halsey, Johns Hopkins Bloomberg School of Public Health Stephen Hughes, National Cancer Institute Kristin Kenyan, CDC Karla Kirkegaard, Stanford University School of Medicine Mauricio Landaverde, Pan American Health Organization Catherine Laughlin, NIAID, NIH Mark McKinlay, Gentara Corporation Philip Minor, National Institute for Biological Standards and Control, UK

OCR for page 69
Exploring the Role of Antiviral Drugs in the Eradication of Polio: Workshop Report Akhter Molla, Abbott Laboratories Mark Pallansch, CDC Amy Patick, Pfizer Olve Peersen, Colorado State University Jane Seward, CDC Tim Skern, Medical University of Vienna Roland Sutter, WHO Kimberly Thompson, Harvard School of Public Health Linda Venczel, CDC Margie Watkins, CDC Jerry Winkelstein, Johns Hopkins Children’s Center Peter Wright, Vanderbilt University School of Medicine Staff from the National Academies Board on Life Sciences Ann Reid, Study Director Anne Jurkowski, Program Assistant Fran Sharples, Director, Board on Life Sciences